ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.

Zhejiang AngLiKang Pharmaceutical CO.,LTD.

002940

CNE100003GC2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 02/07/2024 am IST			5-day change	1st Jan Change
15.4 ^CNY	+4.19%		+8.53%	-29.06%

02/07	Anglikang Pharmaceutical's Two Drugs Get Marketing Nod	MT
07/06	Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on Share A for the Year 2023, Payable on June 17, 2024	CI

Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on Share A for the Year 2023, Payable on June 17, 2024

June 08, 2024 at 01:03 am IST

Zhejiang AngLiKang Pharmaceutical CO.,LTD. announced Cash dividend/10 shares (tax included): CNY 2.10000000 on share A for the year 2023, Record date: 14 June 2024, Ex-date: 17 June 2024, Payment date: 17 June 2024.

Latest news about Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Anglikang Pharmaceutical's Two Drugs Get Marketing Nod	02/07	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on Share A for the Year 2023, Payable on June 17, 2024	08/06	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	02/04	CI
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug	06/02	MT
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets	29/01	MT
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	02/01	CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	10/23/10	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.	30/23/30	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.	30/23/30	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates	17/23/17	MT
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China	27/23/27	MT
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China	16/23/16	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023	13/23/13	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022	25/23/25	CI
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm	06/23/06	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022	03/23/03	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Anglikang Pharma’s Drug to Lower Hypertension Fails to Make It on China’s Drug Procurement List	30/23/30	MT
Chinese Shares End Mixed; Anglikang Pharma Slides 8% on 191 Million Yuan M&A Plan	24/23/24	MT
Zhejiang Anglikang Pharma to Boost Stake in Local Biopharma Firm to 62% For 191 Million Yuan	24/23/24	MT
Zhejiang AngLiKang Pharmaceutical CO.,LTD. completed the acquisition of an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin.	22/23/22	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/22/24	CI

Chart Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Duration

Period

Chart Zhejiang AngLiKang Pharmaceutical CO.,LTD.

More charts

Company Profile

Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a China-based company principally engaged in the research, development, production and sales of chemical raw materials and preparations. The Company's products mainly include cephalosporin and penicillin series, anti-hypertension series, digestive system series, kidney disease series and others.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.	-29.06%	41Cr
ELI LILLY AND COMPANY	+55.55%	82TCr
NOVO NORDISK A/S	+42.31%	64TCr
JOHNSON & JOHNSON	-6.83%	35TCr
MERCK & CO., INC.	+17.15%	32TCr
ABBVIE INC.	+7.09%	30TCr
ASTRAZENECA PLC	+14.02%	24TCr
ROCHE HOLDING AG	+1.64%	22TCr
NOVARTIS AG	+13.66%	22TCr
AMGEN INC.	+7.87%	17TCr